Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Awaits US Appeal Ruling On Sandoz’ Enbrel Biosimilar

Sandoz’ Erelzi Version Held Up By IP Barriers

Executive Summary

Sandoz’ attempts to imminently break into the $5bn Enbrel market in the US rest largely on a Court of Appeals ruling that would have to reverse an unfavorable district court decision issued in August last year. A decision may be forthcoming in the next few weeks.

You may also be interested in...

What's Next? Five Things To Look Out For In July

In the month ahead, Mylan and Upjohn will at last begin to make final preparations for their proposed combination while second-quarter results are expected from large cap companies including Novartis’ Sandoz, Amgen, Biogen and Pfizer.

Sandoz Will Appeal Against US Enbrel Patent Setback

Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid. 

Samsung Bioepis Added To Avastin Biosimilar Litigants

Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts